文献速递基层心理健康慢病管理

米氮平联合SSRI或SNRI治疗基层难治性抑郁:III期随机安慰剂对照试验

Mirtazapine added to SSRIs or SNRIs for treatment resistant depression in primary care: phase III randomised placebo controlled trial (MIR).
PubMed 文献 · BMJ · 2018-10-31

该III期多中心随机安慰剂对照试验纳入480例基层难治性抑郁成人患者,比较米氮平联合SSRI或SNRI与安慰剂联合SSRI或SNRI的疗效。12周时米氮平组Beck抑郁量表II评分较安慰剂组低1.83分,但95%CI包含无效值(-3.92至0.27,P=0.09),未发现具临床重要意义的获益;米氮平组不良事件更常见且与停药相关。

要点

  • 米氮平联合SSRI或SNRI较安慰剂未显示临床重要获益(调整后均值差-1.83,95%CI -3.92至0.27,P=0.09)。
  • 米氮平组不良事件更常见,且与受试者停用试验药物相关。
  • 基层难治性抑郁仍是有效治疗证据有限的重要未满足需求领域。

核心结论

  • 在基层难治性抑郁患者中,米氮平联合SSRI或SNRI较安慰剂联合SSRI或SNRI未发现具临床重要意义的获益。

研究设计与样本

  • 两平行组多中心III期随机安慰剂对照试验,纳入英国四地106家全科诊所,2013年8月至2015年10月。
  • 纳入480例18岁及以上、Beck抑郁量表第二版评分≥14且符合ICD-10抑郁标准、已使用SSRI或SNRI至少六周但仍抑郁的成人。
  • 241例随机至米氮平组、239例至安慰剂组,均在常规SSRI或SNRI治疗基础上加用;按中心分层并按基线Beck评分、性别及当前心理治疗进行最小化。
  • 于12、24、52周随访,431例(89.8%)纳入主要12周随访分析。

主要发现

  • 12周时米氮平组Beck抑郁量表II平均(SD)评分为18.0(12.3),安慰剂组为19.7(12.4)。
  • 调整基线评分及最小化或分层变量后,两组均值差为-1.83(95%CI -3.92至0.27),P=0.09。
  • 米氮平组不良事件更常见,且与受试者停用试验药物相关。

关键数值与推荐

  • 主要结局为随机后12周Beck抑郁量表II评分,作为连续变量分析。
  • 次要结局包括12、24、52周焦虑、生活质量及不良事件测量。

临床怎么用

  • 对已用SSRI或SNRI至少六周仍抑郁的基层患者,加用米氮平较安慰剂未显示临床重要获益,决策时需结合不良事件风险。
  • 米氮平组不良事件更常见且与停药相关,加用前应与患者讨论耐受性。

局限性

  • 12周主要随访中431例(89.8%)被纳入分析,存在失访。
  • 主要结局的置信区间包含无效值(P=0.09),不能排除微小差异。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To investigate the effectiveness of combining mirtazapine with serotonin-noradrenaline reuptake inhibitor (SNRI) or selective serotonin reuptake inhibitor (SSRI) antidepressants for treatment resistant depression in primary care. DESIGN: Two parallel group multicentre phase III randomised placebo controlled trial. SETTING: 106 general practices in four UK sites; Bristol, Exeter, Hull, and Keele/North Staffs, August 2013 to October 2015. PARTICIPANTS: 480 adults aged 18 or more years who scored 14 or more on the Beck depression inventory, second revision, fulfilled ICD-10 (international classification of diseases, 10th revision) criteria for depression, and had used an SSRI or SNRI for at least six weeks but were still depressed. 241 were randomised to mirtazapine and 239 to placebo, both given in addition to usual SSRI or SNRI treatment. Participants were stratified by centre and minimised by baseline Beck depression inventory score, sex, and current psychological therapy. They were followed up at 12, 24, and 52 weeks. 431 (89.8%) were included in the (primary) 12 week follow-up. MAIN OUTCOME MEASURES: Depressive symptoms at 12 weeks after randomisation, measured using the Beck depression inventory II score as a continuous variable. Secondary outcomes included measures of anxiety, quality of life, and adverse effects at 12, 24, and 52 weeks. RESULTS: Beck depression inventory II scores at 12 weeks were lower in the mirtazapine group after adjustment for baseline scores and minimisation or stratification variables, although the confidence interval included the null (mean (SD) scores at 12 weeks: 18.0 (12.3) in the mirtazapine group, 19.7 (12.4) in the placebo group; adjusted difference between means -1.83 (95% confidence interval -3.92 to 0.27); P=0.09). Adverse effects were more common in the mirtazapine group and were associated with the participants stopping the trial drug. CONCLUSION: This study did not find evidence of a clinically important benefit for mirtazapine in addition to an SSRI or SNRI over placebo in a treatment resistant group of primary care patients with depression. This remains an area of important unmet need where evidence of effective treatment options is limited. TRIAL REGISTRATION: Current Controlled Trials ISRCTN06653773.

来源:BMJ,查看原文。版权归原作者所有。

引用

  1. Kessler DS, MacNeill SJ, Tallon D, et al. Mirtazapine added to SSRIs or SNRIs for treatment resistant depression in primary care: phase III randomised placebo controlled trial (MIR). BMJ. 2018. PMID: 30381374. doi:10.1136/bmj.k4218

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。